Showing results (81-90 of 95) with videos related to

Sort By:
Pageof 10
European Journal of Medicinal Chemistry|May 31, 2023
Discovery of quinazolin-4-one-based non-covalent inhibitors targeting the severe acute respiratory syndrome coronavirus 2 main protease (SARS-CoV-2 Mpro)Kuojun Zhang, Tianyu Wang, Maotian Li, et al.
IUBMB Life|January 16, 2025
APOC1 inhibit NKTCL doxorubicin sensitivity by promoting mitophagySa Xiao, Jing Kuang, Jiamei Yang, et al.
Oxidative Medicine and Cellular Longevity|December 13, 2019
lncRNA AK054386 Functions as a ceRNA to Sequester miR-199 and Induce Sustained Endoplasmic Reticulum Stress in Hepatic Reperfusion InjuryBinghua Dai, Liang Qiao, Mingke Zhang, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 6, 2020
Rational combination therapy for hepatocellular carcinoma with PARP1 and DNA-PK inhibitorsChen Wang, Huanyin Tang, Anke Geng, et al.
BMC Cancer|March 4, 2018
Safety assessment of sorafenib in Chinese patients with unresectable hepatocellular carcinoma: subgroup analysis of the GIDEON studySheng-Long Ye, Jiamei Yang, Ping Bie, et al.
Journal of Hepatology|January 26, 2016
Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trialRiccardo Lencioni, Josep M Llovet, Guohong Han, et al.
Oncotarget|January 7, 2016
Safety and efficacy of sorafenib therapy in patients with hepatocellular carcinoma: final outcome from the Chinese patient subset of the GIDEON studySheng-Long Ye, Xiaoping Chen, Jiamei Yang, et al.
The Lancet. Gastroenterology & Hepatology|January 9, 2022
Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trialXiangrui Meng, Tao Wu, Yonggui Hong, et al.
The Lancet. Oncology|September 13, 2015
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trialJordi Bruix, Tadatoshi Takayama, Vincenzo Mazzaferro, et al.
Molecular Therapy. Methods & Clinical Development|February 3, 2025
The combination of rAAV pseudo-lipid nanoparticle and triamcinolone acetonide enables multi-administration to liverChunmei Gan, Mi Leng, Yu Liu, et al.
Pageof 10